emjreviews.com1d
Elevated Cardiovascular Disease Risk in Patients with Hidradenitis Suppurativa
Patients with hidradenitis suppurativa are more likely to develop cardiovascular disease, according to the largest study ...
The Globe and Mail1d
Health Canada approves Cosentyx®, a biologic therapy, for the treatment of adults with moderate to severe Hidradenitis Suppurativa (HS)
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication. The close: Stocks fall despite Nvidia boost as U.S.
Medindia2d
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX ® (bimekizumab-bkzx), in the treatment ...
Pharmaceutical Technology5d
Upadacitinib ER by AbbVie for Hidradenitis Suppurativa: Likelihood of Approval
Upadacitinib ER is under clinical development by AbbVie and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III drugs for Hidradenitis Suppurativa have a 100% phase ...
Pharmaceutical Technology5d
Remibrutinib by Novartis for Hidradenitis Suppurativa: Likelihood of Approval
Remibrutinib is under clinical development by Novartis and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase ...